News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 08 - 17

Efung Honor | Efung Capital Selected for Two Awards fromTitan Media Venture Capital

Today, Titan Media Venture Capital unveiled the prestigious "2026 H1 Pioneer List."Efung Capital was honored with dual accolades:Biopharmaceutical Sector TOP20Venture Capital Institution TOP20If one word could define China's venture capital landscape in the first half of 2026, there would be no halftime break—only relentless acceleration.Fundraising operates on a dual-track system. On the RMB side, state-owned capital continues to deploy aggressively. In April alone, 665 new funds were registered, up nearly 60% year-on-year, with state-backed funds averaging nearly RMB 500 m...

浏览次数：7

查看详情>>

发布时间: 2026 - 08 - 10

Efung Hard Talk | From Sequence Rewriting to “Software” Rewriting

Over the past decade, the main thread of gene therapy has been "rewriting hardware"—from gene supplementation to CRISPR gene editing. Their shared logic is direct modification of the DNA itself: either supplying a functional gene or cutting and rewriting genomic sequences. However, this path carries inherent risks, including genotoxicity, off-target effects, and irreversibility.In recent years, a new class of technologies has been rapidly advancing from concept to clinic—epigenome editing. Its hallmark is that it does not alter the DNA sequence but instead rewrites the "software...

浏览次数：13

查看详情>>

发布时间: 2026 - 08 - 07

Efung Honor | Efung Capital Honored with Dual Awards in [FirstNewVoice] 2026 Q2 China's Most Active

Recently, the [FirstNewVoice] 2026 Q2 China's Most Active Institutions Series List was grandly released. Efung Capital was honored with the Top 30 Most Active Venture Capital Institutions in China for Q2 2026 and the Top 10 Most Active Investment Institutions in Healthcare.In the second quarter of 2026, China's equity investment market accelerated its differentiation amid structural recovery, with investment logic, valuation systems, and exit pathways undergoing deeper-level restructuring. According to FirstNewVoice's continuous tracking research over 22 consecutive ...

浏览次数：5

查看详情>>

发布时间: 2026 - 08 - 06

Efung News | Northchip Life's LotosPFA® Approved for Market Launch! The World's First RCT-Validated

On August 5, 2026, the National Medical Products Administration (NMPA) issued an announcement officially approving the market launch applications for the "Cardiac Pulsed Field Ablation Generator" and the "Single-Use Cardiac Pulsed Field Ablation Catheter," independently developed by Northchip Medical, a subsidiary of Shenzhen Northchip Life Technology Co., Ltd. ("Northchip Life"), under the trade name LotosPFA®. This marks the official entry of PFA into a new era of "routine local anesthesia."The system is the world's first pulsed field ablation...

浏览次数：23

查看详情>>